Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; “ONO”) announced that the “ONO Pharmaceutical and Dr. Honjo Honorary Research Fund” has been established at Kyoto University, a National University, with donation of JPY23 billion on our own voluntary will.

　We believe that open innovation with the world top-class academia is a lifeline for ONO, as we have discovered and developed innovative new drugs such as prostaglandin-related products and Opdivo. We have shown a new form of the industry-academia collaboration in Japan, and have been considering internally potential contributions to the expansion of economic foundation for the improvement of future education and research environment and for education and research support projects in academia.

　We sincerely hope that the establishment of this fund will lead to the further development of medical and pharmaceutical research in Japan by providing an environment where young researchers with their strong aspirations and high qualifications can play an active role in the field of natural sciences, mainly life sciences at Kyoto University.